Skip to main content
TipRanks
Go Ultimate75% OFF

Innate Pharma presents initial IPH4502 study data

Innate Pharma (IPHA) announced initial Phase 1 data from its ongoing study of IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate, or ADC, incorporating an exatecan payload, in patients with advanced solid tumors. The results are being presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The Phase 1 dose-escalation study of IPH4502 enrolled 76 patients with advanced solid tumors across six dose levels ranging from 0.6 mg/kg to 3.6 mg/kg, administered once every three weeks. Patients were heavily pretreated, with a median of 3.5 prior lines of systemic therapy and represented more than 10 tumor types. Nineteen patients had urothelial cancer, or UC, all of whom had previously received Padcev. The primary objective of the study was to assess the safety and tolerability of IPH4502, while secondary objectives include evaluating its pharmacokinetics and antitumor activity in patients with advanced solid tumors. As of the August 17 data cutoff, IPH4502 was well-tolerated during Phase 1 dose escalation, with low overall hematologic toxicity. The maximum tolerated dose was established at 3.6 mg/kg administered once every three weeks, with stomatitis as the only reported dose-limiting toxicity. No febrile neutropenia or hematologic dose-limiting toxicities were reported, and no signal of peripheral neuropathy was observed. Grade 3 or higher treatment-emergent adverse events, or TEAEs, were reported in 43.4% of patients, including Grade 3 or higher anemia in 11.8%. Stomatitis occurred in 27.6% of patients overall, including 3.9% with Grade 3 or higher events. TEAEs led to dose reductions in 7.9% of patients and treatment discontinuations in 5.3%. As of the August 17 data cutoff, antitumor activity was observed across multiple dose levels, tumor types and Nectin-4 expression levels. Objective responses were observed in patients in several tumor types and across low, moderate and high Nectin-4 expression levels. At the maximum tolerated dose of 3.6 mg/kg, an objective response rate, or ORR, of 33% was observed in patients with non-urothelial tumors. In urothelial cancer, 19 patients were enrolled, with a median of three prior lines of systemic therapy; all had previously received enfortumab vedotin. Out of these 19 patients, 15 were enrolled at 2.4 or 2.8 mg/kg, 4 at 3.2 mg/kg and none at 3.6 mg/kg. At these intermediate dose levels, antitumor activity was observed, with 3 partial responses and tumor shrinkage in the majority of patients. The unconfirmed disease control rate was 68.4%. Phase 1 dose optimization is being initiated in second-line or later urothelial cancer following enfortumab vedotin, to further characterize safety and activity in post-EV urothelial cancer at upper dose levels. The first patient is planned in the first half of 2027. The study will evaluate split dosing on Days 1 and 8 of each three-week cycle with mandatory prophylaxis to help reduce stomatitis and inform selection of a recommended Phase 2 dose and schedule.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

Add as preferred source